The pathological role and prognostic impact of miR-181 in acute myeloid leukemia

Cancer Genetics

Volumn 208, Issue 5, 2015, Pages 225-229

  Weng, Hengyou ^a   Lal, Kumar ^a,b   Yang, Frank F ^a,c   Chen, Jianjun ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b RUSH MEDICAL COLLEGE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acute myeloid leukemia; Diagnostic marker; MiR 181; Prognostic predictor; Tumor suppressor

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; LENALIDOMIDE; MICRORNA; MICRORNA 181; MICRORNA 181A; MICRORNA 181B; PROTEIN P30; UNCLASSIFIED DRUG; MIRN181 MICRORNA, HUMAN; TUMOR MARKER;

ACUTE MYELOBLASTIC LEUKEMIA; B LYMPHOCYTE DIFFERENTIATION; CANCER INHIBITION; CANCER RESEARCH; CANCER SURVIVAL; CHROMOSOME ANALYSIS; CHROMOSOME TRANSLOCATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; HEMATOPOIESIS; HEMATOPOIETIC CELL; HISTONE MODIFICATION; HUMAN; LEUKEMIA RELAPSE; LEUKEMOGENESIS; LYMPHOCYTE DIFFERENTIATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NATURAL KILLER T CELL; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SOMATIC MUTATION; T LYMPHOCYTE; GENETIC EPIGENESIS; GENETICS; LEUKEMIA, MYELOID, ACUTE; MORTALITY; PHYSIOLOGY; TUMOR SUPPRESSOR GENE;

BIOMARKERS, TUMOR; EPIGENESIS, GENETIC; GENES, TUMOR SUPPRESSOR; HEMATOPOIESIS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICRORNAS; PROGNOSIS;

EID: 84930572285     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergen.2014.12.006     Document Type: Review

References (43)

1. Tenen D.G. Disruption of differentiation in human cancer: AML shows the way. Nat Rev Cancer 2003, 3:89-101.
2. Chen J., Odenike O., Rowley J.D. Leukaemogenesis: more than mutant genes. Nat Rev Cancer 2010, 10:23-36.
3. Heerema-McKenney A., Arber D.A. Acute myeloid leukemia. Hematol Oncol Clin North Am 2009, 23:633-654.
4. Fatica A. Noncoding RNAs in Acute myeloid leukemia: from key regulators to clinical players. Scientifica (Cairo) 2012, 2012:925758.
5. Shih A.H., Abdel-Wahab O., Patel J.P., et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012, 12:599-612.
6. Mrózek K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109:431-448.
7. Meyer S.C., Levine R.L. Translational implications of somatic genomics in acute myeloid leukaemia. Lancet Oncol 2014, 15:e382-e394.
8. Wu W., Sun M., Zou G.M., et al. MicroRNA and cancer: current status and prospective. Int J Cancer 2007, 120:953-960.
9. Esquela-Kerscher A., Slack F.J. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006, 6:259-269.
10. Calin G.A., Croce C.M. MicroRNA signatures in human cancers. Nat Rev Cancer 2006, 6:857-866.
11. Lu J., Getz G., Miska E.A., et al. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838.
12. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 2004, 5:522-531.
13. Chen C.Z., Li L., Lodish H.F., et al. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
14. Garzon R., Croce C.M. MicroRNAs in normal and malignant hematopoiesis. Curr Opin Hematol 2008, 15:352-358.
15. Cichocki F., Felices M., McCullar V., et al. Cutting edge: microRNA-181 promotes human NK cell development by regulating Notch signaling. JImmunol 2011, 187:6171-6175.
16. Li X., Zhang J., Gao L., et al. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ 2012, 19:378-386.
17. Mi S., Lu J., Sun M., et al. MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A 2007, 104:19971-19976.
18. Li Z., Lu J., Sun M., et al. Distinct microRNA expression profiles in acute myeloid leukemia with common translocations. Proc Natl Acad Sci U S A 2008, 105:15535-15540.
19. Debernardi S., Skoulakis S., Molloy G., et al. MicroRNA miR-181a correlates with morphological sub-class of acute myeloid leukaemia and the expression of its target genes in global genome-wide analysis. Leukemia 2007, 21:912-916.
20. Isken F., Steffen B., Merk S., et al. Identification of acute myeloid leukaemia associated microRNA expression patterns. Br J Haematol 2008, 140:153-161.
21. Marcucci G., Maharry K., Radmacher M.D., et al. Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. JClin Oncol 2008, 26:5078-5087.
22. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. NEngl J Med 2008, 358:1919-1928.
23. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111:3183-3189.
24. Yuan Y., Kasar S., Underbayev C., et al. MicroRNAs in acute myeloid leukemia and other blood disorders. Leuk Res Treatment 2012, 2012:603830.
25. Wang Y., Li Z., He C., et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis 2010, 44:191-197.
26. Hickey C.J., Schwind S., Radomska H.S., et al. Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013, 121:159-169.
27. Schwind S., Maharry K., Radmacher M.D., et al. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. JClin Oncol 2010, 28:5257-5264.
28. Li Z., Huang H., Li Y., et al. Up-regulation of a HOXA-PBX3 homeobox-gene signature following down-regulation of miR-181 is associated with adverse prognosis in patients with cytogenetically abnormal AML. Blood 2012, 119:2314-2324.
29. Garzon R., Marcucci G., Croce C.M. Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 2010, 9:775-789.
30. Marcucci G., Haferlach T., Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. JClin Oncol 2011, 29:475-486.
31. Sugimura K., Miyata H., Tanaka K., et al. Let-7 expression is a significant determinant of response to chemotherapy through the regulation of IL-6/STAT3 pathway in esophageal squamous cell carcinoma. Clin Cancer Res 2012, 18:5144-5153.
32. Weng H., Huang H., Dong B., et al. Inhibition of miR-17 and miR-20a by oridonin triggers apoptosis and reverses chemoresistance by derepressing BIM-S. Cancer Res 2014, 74:4409-4419.
33. Taylor M.A., Sossey-Alaoui K., Thompson C.L., et al. TGF-β upregulates miR-181a expression to promote breast cancer metastasis. JClin Invest 2013, 123:150-163.
34. Ji D., Chen Z., Li M., et al. MicroRNA-181a promotes tumor growth and liver metastasis in colorectal cancer by targeting the tumor suppressor WIF-1. Mol Cancer 2014, 13:86.
35. Bai H., Cao Z., Deng C., et al. miR-181a sensitizes resistant leukaemia HL-60/Ara-C cells to Ara-C by inducing apoptosis. JCancer Res Clin Oncol 2012, 138:595-602.
36. Lu F., Zhang J., Ji M., et al. miR-181b increases drug sensitivity in acute myeloid leukemia via targeting HMGB1 and Mcl-1. Int J Oncol 2014, 45:383-392.
37. Garzon R., Pichiorri F., Palumbo T., et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26:4148-4157.
38. Wang X., Gocek E., Liu C.G., et al. MicroRNAs181 regulate the expression of p27Kip1 in human myeloid leukemia cells induced to differentiate by 1,25-dihydroxyvitamin D3. Cell Cycle 2009, 8:736-741.
39. Su R., Lin H.S., Zhang X.H., et al. MiR-181 family: regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene 2014, [Epub ahead of print].
40. Faber J., Krivtsov A.V., Stubbs M.C., et al. HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2009, 113:2375-2385.
41. Calvo K.R., Knoepfler P.S., Sykes D.B., et al. Meis1a suppresses differentiation by G-CSF and promotes proliferation by SCF: potential mechanisms of cooperativity with Hoxa9 in myeloid leukemia. Proc Natl Acad Sci U S A 2001, 98:13120-13125.
42. Beverly L.J., Varmus H.E. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene 2009, 28:1274-1279.
43. Jiang X., Huang H., Li Z., et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell 2012, 22:524-535.